COMPANY SUMMARY
BIO Boston 1x1 meeting

FAB’ENTECH

NAME OF THE CEO
Bertrand LEPINE

ADDRESS
24, rue Jean Baldassini,
69007 LYON, France

EMAIL
Raphael.metrop@fabentech.com
Bertrand.lepine@fabentech.com
www.fabentech.fr

MANAGEMENT TEAM
Bertrand LEPINE: CEO & Founder
Raphaël METROP: Head of Corporate Business Development
Ludovic NGUYEN: Head of Industrial Operations
Charlotte REYNAUD DESREUX: Managing Director & Head of Pharmaceutical Affairs
Cécile HERBRETEAU DELALE: Head of Research & Development

MISSION
Fab’entech develops and manufactures specific polyclonal immunotherapies to address situations of emergency. In addition, Fab’entech also recently decides to apply its technology on other medical needs and to focus on intoxications with antidote candidates in the fields of biodefense, drug intoxication, anti-venom and nosocomial infections.

TECHNOLOGY
F(ab’)2 platform is used for the development and manufacturing of immunotherapies composed of highly purified F(ab’)2 fragments of horse specific polyclonal immunoglobulins. This technology has been developed by Sanofi Pasteur, then licensed by Fab’entech and fully-validated with the development of Fabenflu®, a treatment of H5N1 infections in humans (orphan drug status in Europe and Australia).

COMPETITION
• BTG
• Micropharm
• Emergent Biosolutions

ALLIANCES/PARTNERSHIPS
Current partnerships with the French army and private industrial partners for the development of Antidotes & Biodefense candidates.
Other partnerships: Sanofi Pasteur - BPIfrance - INSERM-ENS (France) - European community (EC) - WHO - NIH (USA) - USAMRIID (USA) - Winnipeg University (Canada) - CSIRO (Australia)

Fab’entech is seeking to raise new funding to support the development of additional candidates in the field of biodefense, antidotes, and nosocomial infections (to supplement antibiotic effect), and therefore its business development efforts within these fields.

UPCOMING CATALYSTS
• Completion of the preclinical development of Ebola virus candidate in collaboration in particular with NIH (US)
• Completion of the development for biodefense antidote #1, in partnership with the French Army, available for international markets as well
• Ongoing discussions with industrials for the development of antidote #2 for drug intoxication (confidential)
• Investment in its proprietary US and EMA GMP manufacturing facility based on innovative and flexible modular approach that can also be deployed in interested territories
• New significant funding in 2018 by current shareholders to support the development of the company

PRIVATE COMPANY
CREATION DATE
2009
By 2022, Fab’entech will be at breakeven, generating recurrent revenues from its core antidotes range (2 antidotes on the market), and capitalizing on its private industrial partners to address more valuable markets (1 nosocomial candidate in clinics).